Ratings Bodal Chemicals Limited

Equities

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-05-10 EDT			5-day change	1st Jan Change
72.55 ^INR	+1.00%		-5.91%	-12.40%

03-06	Bodal Chemicals Limited announced that it expects to receive INR 214 million in funding	CI
02-13	Transcript : Bodal Chemicals Limited, Q3 2024 Earnings Call, Feb 13, 2024

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.
With an expected P/E ratio at 120.92 and 19.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

	1st Jan change	Capi.	ESG Refinitiv
BODAL CHEMICALS LIMITED	-12.40%	109M	-
SIKA AG	+1.61%	49.2B	A-
GIVAUDAN SA	+16.33%	41.24B	B+
FUJIFILM HOLDINGS CORPORATION	+18.68%	25.89B	A-
EMS-CHEMIE HOLDING AG	+12.78%	19.81B	C+
CELANESE CORPORATION	+0.85%	17.48B	B+
POSCO FUTURE M CO., LTD.	-21.87%	15.86B	A-
SYMRISE AG	+2.32%	15.35B	B+
ALBEMARLE CORPORATION	-10.29%	15.23B	C+
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-22.30%	13.36B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality